Summary

EXACT Therapeutics (“EXACT-Tx“) is a clinical-stage biopharmaceutical company developing a novel ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions.

On the 14th of July 2020, EXACT-Tx AS was admitted to the Oslo Stock Exchange list ‘Euronext Growth’ under EXTX-ME.

For more information about the EXACT-Tx share please visit the Oslo Børs webpage.

Click here to download the Euronext Growth Market admission document.

John M. Edminson - CFO
EXACT Therapeutics
Email: john.edminson@exact-tx.com